A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Recruiting now · Phase 1
Conditions studied: Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors, Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer
In brief
This is a first-in-human (FIH) clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of BGB-B2033 administered as monotherapy and in combination with tislelizumab, with or without bevacizumab. The study will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC), alpha-fetoprotein (AFP)-producing gastric cancer (GC), extragonadal yolk sac tumors/non-dysgerminomas, or glypican-3 (GPC3)-positive squamous non-small cell lung cancer (NSCLC).
Key facts
- Study ID
- NCT06427941
- Run by
- BeOne Medicines
- People needed
- 392
- Starts
- 2024-07-23
- Expected to finish
- 2028-05-30
- Last updated by the study team
- 2026-07-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope Phoenix Cancer Center — Goodyear, Arizona, United States (enrolling)
- City of Hope National Medical Center — Duarte, California, United States (enrolling)
- City of Hope Chicago Cancer Center — Zion, Illinois, United States (enrolling)
- Memorial Sloan Kettering Cancer Center Mskcc — New York, New York, United States (enrolling)
- Upmc Hillman Cancer Center(Univ of Pittsburgh) — Pittsburgh, Pennsylvania, United States (enrolling)
- Scri Oncology Partners — Nashville, Tennessee, United States (enrolling)
- The University of Texas Md Anderson Cancer Center — Houston, Texas, United States (enrolling)
- Centro Gaucho Integrado de Oncologia Hospital Mae de Deus — Porto Alegre, Brazil (enrolling)
- Hospital Da Bahia — Salvador, Brazil (enrolling)
- Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto — São José do Rio Preto, Brazil (enrolling)
- Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira — São Paulo, Brazil (enrolling)
- Anhui Provincial Hospital — Hefei, Anhui, China (enrolling)
- Chongqing University Cancer Hospital — Chongqing, Chongqing Municipality, China (enrolling)
- Mengchao Hepatobiliary Hospital of Fujian Medical University — Fuzhou, Fujian, China (enrolling)
- Zhujiang Hospital of Southern Medical University — Guangzhou, Guangdong, China (enrolling)
- Nanfang Hospital of Southern Medical University — Guangzhou, Guangdong, China (enrolling)
- Guangxi Medical University Cancer Hospital Wuxiang Branch — Nanning, Guangxi, China (enrolling)
- The Fourth Hospital of Hebei Medical University — Shijiazhuang, Hebei, China (enrolling)
- Harbin Medical University Cancer Hospital — Harbin, Heilongjiang, China (enrolling)
- Union Hospital of Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei, China (enrolling)
- Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology — Wuhan, Hubei, China (enrolling)
- Hunan Cancer Hospital — Changsha, Hunan, China (enrolling)
- The Affiliated Hospital of Xuzhou Medical University — Xuzhou, Jiangsu, China (enrolling)
- The Second Affiliated Hospital of Nanchang University — Nanchang, Jiangxi, China (enrolling)
- The Second Affiliated Hospital of Nanchang Universityhongjiaozhou Branch — Nanchang, Jiangxi, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.